Email this article 
Cardiovascular and metabolic problems associated with application of second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
- Authors: Vinogradova O.Y.1,2
-
Affiliations:
- Federal Research Center of Pediatric Hematology, Oncology, and Immunology named after Dmitry Rogachev, Ministry of Health of Russia
- “N.I. Pirogov Russian National Research Medical University”, Ministry of Health of Russia
- Issue: Vol 10, No 3 (2015)
- Pages: 58-63
- Section: HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE
- Published: 07.10.2015
- URL: https://oncohematology.abvpress.ru/ongm/article/view/154
- DOI: https://doi.org/10.17650/1818-8346-2015-10-3-58-63
- ID: 154
Cite item
Full Text
Abstract
During therapy with second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia, a number of patients demonstrate non-hematological toxicity of various degrees. The article contains review of references about second generation tyrosine kinase inhibitors effect on the frequency of cardiovascular and metabolic problems.
About the authors
O. Y. Vinogradova
Federal Research Center of Pediatric Hematology, Oncology, and Immunology named after Dmitry Rogachev, Ministry of Health of Russia;“N.I. Pirogov Russian National Research Medical University”, Ministry of Health of Russia
Author for correspondence.
Email: olgavinz@mail.ru
1 Samory Mashela St., Moscow, 117198;
1 Ostrovityanovа St., Moscow, 117997
Russian FederationReferences
Supplementary files
